Join Growin Stock Community!

Belite bio, incBLTE.US Overview

US StockHealthcare
(No presentation for BLTE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BLTE AI Insights

BLTE Overall Performance

BLTE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BLTE Recent Performance

-4.42%

Belite bio, inc

0.05%

Avg of Sector

-0.31%

S&P500

BLTE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BLTE Key Information

BLTE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BLTE Profile

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Price of BLTE

BLTE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BLTE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.79
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
25.86
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.79
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
25.86
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BLTE's latest earnings report released?

    The most recent financial report for Belite bio, inc (BLTE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BLTE's short-term business performance and financial health. For the latest updates on BLTE's earnings releases, visit this page regularly.

  • How much debt does BLTE have?

    As of the end of the reporting period, Belite bio, inc (BLTE) had total debt of 510K, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BLTE have?

    At the end of the period, Belite bio, inc (BLTE) held Total Cash and Cash Equivalents of 157.03M, accounting for 0.56 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BLTE's EPS continuing to grow?

    According to the past four quarterly reports, Belite bio, inc (BLTE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.65. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.